<DOC>
	<DOCNO>NCT00820365</DOCNO>
	<brief_summary>This exploratory , open-label , uncontrolled , multi-center , 1-arm study conduct 16 site Bulgaria , Germany Romania . A total ca . 30 - 35 patient receive SC12267 ( 4SC-101 ) tablet , 35 mg daily 12 week . First patient undergo screening period 1 week follow-up visit perform 4 week study drug discontinuation earlier case relapse follow . Total study duration 36 ( +2 ) week . There 8 study visit : one screen visit , 6 visit treatment period one follow-up visit . In addition , four telephone visit perform Week 6 , Week 10 , Week 20 ( +1 ) Week 36 ( +2 ) . The duration entire study ( first patient till last patient ) expect 13 month .</brief_summary>
	<brief_title>SC12267 ( 4SC-101 ) Treatment Patients With Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Criteria regard Crohn´s Disease : Established diagnosis CD , confirm standard criterion ( e.g . endoscopy , ultrasound , Xray ) Patients must clinical remission ( Crohn 's Disease Activity Index [ CDAI ] &lt; 150 point ) steroid therapy least 2 week Confirmed steroiddependency CD : patient either 1. unable taper steroid completely within 3 month start steroid , without recurrent active disease , 2. relapse within 2 month stop steroid Individual threshold* dose previous relapse equal less 20 mg/day Prednisolone equivalent steroid dose Patients stable glucocorticosteroid therapy 20 40 mg/day Prednisolone equivalent steroid dose previous week Criteria regard Ulcerative Colitis : Established diagnosis UC , confirm standard criterion ( e.g . endoscopy , ultrasound , Xray ) Patients must clinical remission ( Clinical Activity Index [ CAI ] &lt; 4 point ) steroid therapy least 2 week Confirmed steroiddependency UC : patient either 1. unable taper steroid completely within 3 month start steroid , without recurrent active disease , 2. relapse within 2 month stop steroid Individual threshold* dose previous relapse equal less 20 mg/day Prednisolone equivalent steroid dose Patients stable glucocorticosteroid therapy 20 40 mg/day Prednisolone equivalent steroid dose previous week ( * The threshold dose dose patient experience relapse ) Criteria regard general requirement : Men woman , 18 70 year age Written inform consent Negative pregnancy test screening female childbearing potential Males willing use condom sexually abstinent Use appropriate contraceptive method females childbearing potential one month , throughout course study one month study termination . This must combination follow : 1. highly effective method first choice = method low failure rate ( i.e . le 1 % per year ) like sexual abstinence , combine oral contraceptive , implant , injectables , Intra Uterine Devices ( IUDs ) , vasectomized partner together 2. method second choice like condom , diaphragm , cup pessary Criteria regard gastrointestinal condition : Short bowel syndrome Ileostomy , colostomy rectal pouch Relapse screen Criteria regard medical history : History existence active tuberculosis History existence urolithiasis History existence human immune deficiency virus ( HIV ) , Hepatitis B C History malignancy within past five year ( exclude basal cell carcinoma skin ) Previous opportunistic infection History serious drug sensitivity Criteria regard concomitant disease : Significant cardiac arrhythmia , bradycardia tachycardia significant find electrocardiogram ( ECG ) Congestive heart failure Uncontrolled arterial hypertension Uncontrolled asthma Renal disease Renal insufficiency define glomerular filtration rate ( GRF ) &lt; 50 ml/min/1.73 m² ( estimate GRF accord CockcroftGault ) Psychiatric illness Known suspect immunodeficiency Laboratory abnormality : hemoglobin &lt; 8.5 g/dl , white blood cell count &lt; 3500/mm³ , platelet count &lt; 125 000/mm³ , clinically relevant elevation liver enzymes , serum creatinine level &gt; =1.4 mg/dl , hematuria ( &gt; =10 erythrocytes/field dipstick ) Criteria regard concomitant circumstance : Pregnancy , lactation History alcohol and/or drug dependence Heavy smoking ( 20 cigarette per day ) Use prohibit drug treatment Patient able willing follow study procedure due physical psychological limitation language problem Participation another investigational drug vaccine trial within last three month concurrently study Vaccination life attenuate virus within 4 week prior study start Patient medical condition , opinion investigator designee , could jeopardize compromise ability patient participate trial Patients possibly dependent investigator sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Inflammatory Bowel Disease ( IBD )</keyword>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Ulcerative Colitis</keyword>
	<keyword>SC12267</keyword>
	<keyword>4SC-101</keyword>
	<keyword>Phase II</keyword>
</DOC>